Flow Pharma

Flow Pharma is a private, pre-clinical stage biotech focused on immunotherapy using its proprietary FlowVax platform. The platform utilizes AI-designed synthetic peptides encapsulated in precisely constructed microspheres to stimulate targeted cytotoxic T-lymphocyte (CTL) responses. Its lead programs target COVID-19 (FLOVID-20) and treatment-resistant cancers like triple-negative breast cancer, with all assets currently in pre-clinical or research stages pending FDA approval. The company emphasizes a scalable, room-temperature stable dry powder format suitable for inhalation or injection.

FlowVax platform: AI-designed synthetic peptide epitopes encapsulated in precisely constructed, room-temperature stable microspheres for targeted cytotoxic T-lymphocyte (CTL) stimulation. Administered as a dry powder via inhalation or injection.

Faces competition from numerous large pharmaceutical companies with approved COVID-19 vaccines and cancer immunotherapies (e.g., mRNA vaccines, checkpoint inhibitors). Also competes with other biotechs developing peptide vaccines, T-cell therapies, and novel delivery platforms. Differentiation hinges on proving superior T-cell stimulation with a stable, convenient format.